TABLE 2.
Antimicrobial susceptibility of 442 Pseudomonas aeruginosa isolates a
| Antimicrobials | Antimicrobial susceptibility (N = 442) | ||
|---|---|---|---|
| Susceptible | Intermediate | Resistant | |
| Ticarcillin-clavulanate | 37.3% (165) | 21.7% (96) | 41% (181) |
| Cefepime | 0.72 (318) | 20.8% (92) | 7.2% (32) |
| Ceftazidime | 74.4% (329) | 5.2% (23) | 20.4% (90) |
| Amikacin | 93.2% (412) | 1.8% (8) | 5% (22) |
| Tobramycin | 91.4% (404) | 1.1% (5) | 7.5% (33) |
| Meropenem | 61.8% (273) | 9.5% (42) | 28.7% (127) |
| Imipenem | 0.61 (270) | 0.5% (2) | 38.5% (170) |
| Ciprofloxacin | 0.79 (349) | 10.6% (47) | 10.4% (46) |
| Levofloxacin | 63.8% (282) | 9.5% (42) | 26.7% (118) |
| Colistin | 95.9% (424) | – | 4.1% (18) |
a
The numbers in the table refer to the percentages of isolates showing susceptibility, intermediate susceptibility, and resistance to each antimicrobial. The numbers in parentheses indicate the number of isolates. –, not applicable.